{"id":"NCT03525210","sponsor":"Universitaire Ziekenhuizen KU Leuven","briefTitle":"Study of Safety, Tolerability and Immunogenicity of Gardasil速9 in Immunocompromised Patients","officialTitle":"An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil速9) in Solid Organ Transplant Recipients and HIV-infected Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-04","primaryCompletion":"2019-09-01","completion":"2020-07-15","firstPosted":"2018-05-15","resultsPosted":"2020-12-11","lastUpdate":"2020-12-11"},"enrollment":271,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Human Papilloma Virus","Hiv","Organ Transplants"],"interventions":[{"type":"BIOLOGICAL","name":"9-valent HPV vaccine","otherNames":["Gardasil9"]}],"arms":[{"label":"HIV patients","type":"OTHER"},{"label":"SOT patients","type":"OTHER"}],"summary":"Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer).\n\nIn this study HIV-patients and SOT-patients will receive 3 doses of Gardasil速9. Safety, tolerability and immunogenicity will be evaluated up to one month following the 3rd and last dose of Gardasil速9.","primaryOutcome":{"measure":"Seroconversion Following 3 Doses of 9-valent HPV Vaccines","timeFrame":"7 months (for each subject)","effectByArm":[{"arm":"HIV Patients","deltaMin":100,"sd":null},{"arm":"SOT Patients","deltaMin":64.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Belgium"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":99},"commonTop":["Injection site pain","Headache","Injection site swelling","injection site erythema"]}}